Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
French open-label phase 4 extension study of long-term avalglucosidase alfa in Pompe disease
2021-002590-26Phase 4Active
- Sponsor
- Sanofi
- Start
- Aug 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of avalglucosidase alfa in Pompe disease, sponsored by Sanofi. Primary endpoint: Number of participants with adverse events. Started Aug 2021; status: active.
02
Drugs
avalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2021-002590-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002590-26.